Myriad Genetics, Inc. (MYGN) is a Healthcare stock trading at $4.54 (as of 2026-06-18), with a market capitalization of $374.96M and a trailing P/E of -0.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Myriad Genetics, Inc. develops and commercializes genetic tests used in clinical decision-making, including molecular diagnostic assays for oncology and women’s and mental health. Its offerings include germline and tumor companion diagnostics and prognostic tests such as MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, and EndoPredict, which it sells in the United States and internationally.